Huadong Medicine

000963 · SZSE

Public Market Listing

000963SZSE

SZSE primary exchange listing

Live quotes, historical charts, and market capitalization for Huadong Medicine are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
1Approved
1Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
PDE4Small molecule
Atopic DermatitisPsoriasis
Phase 3
oxidative stressSmall molecule
Alzheimer's DiseaseAcute Ischemic Stroke
Phase 1/2
BCMAAntibody–drug conjugate
Multiple Myeloma

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (3)
March 2028 (1)
Pamlectabart tismanitinPhase 1/2Multiple Myeloma, Plasma Cell Disorder
Est. primary completion 2028-03 · NCT04879043 · CT.gov ↗
What to watch
April 2028 (1)
Roflumilast (Zoryve)Phase 3Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
Est. primary completion 2028-04-27 · NCT07916480 · CT.gov ↗
What to watch
October 2028 (1)
Edaravone (TTYP01)Phase 2AD, Early Alzheimer's Disease
Est. primary completion 2028-10-23 · NCT07252440 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

23 February 2027FDA action dateRoflumilast (Zoryve)PDUFA target date 23 Feb 2027 for Zoryve cream 0.05% in infant AD
US, FDA · Source ↗

Recent

8 July 2026Filing acceptedRoflumilast (Zoryve)FDA accepts sNDA for Zoryve cream 0.05% in infant atopic dermatitis
US, FDA · Source ↗
29 June 2026ApprovalRoflumilast (Zoryve)FDA approves ZORYVE cream 0.3% for plaque psoriasis in children as young as 2
US, FDA · Source ↗
31 July 2025Filing acceptedEdaravone tablets (TTYP01)NMPA accepts the marketing application for edaravone tablets (TTYP01) in acute ischemic stroke (Huadong Medicine notice 2025-07-31)
CN, NMPA · Shanghai Auzone Biological Technology · Source ↗
30 July 2025Filing acceptedTTYP01NMPA accepts China marketing application for edaravone tablets (TTYP01) in acute ischemic stroke
China, NMPA · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Source ↗
31 March 2025Filing acceptedHDG1901NMPA accepts China marketing application for semaglutide injection (HDG1901) in type 2 diabetes
China, NMPA · Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong Co., Ltd. (wholly owned subsidiary of Huadong Medicine) · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$1.6B———report ↗